Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO6927005 in Mesothelin-Positive Solid Tumors
NCT02317419Phase 1Terminated
- Sponsor
- Roche
- Start
- Dec 2014
- Primary completion
- Aug 2015
- Modality
- Antibody-Drug Conjugates (ADCs), Fc-Fusion Proteins
- Countries
- 4
01
Overview
Phase 1, open-label trial of LMB-100 in solid tumor, pancreatic ductal adenocarcinoma (PDAC) and malignant pleural mesothelioma (MPM) (5 arms), sponsored by Roche. Primary endpoint: Safety and Tolerability. Started Dec 2014; status: terminated.
02
Drugs
LMB-100
03
Conditions
solid tumorpancreatic ductal adenocarcinoma (PDAC)malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT02317419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02317419.